The debut will be the CDMO’s first fully automated sterile injectable manufacturing line at the Wuxi, China site.
WuXi STA—a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry—launched its first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi, China.
With an annual capacity of 12 million units, the new HP injectable manufacturing line is expected to further enhance the company's manufacturing capabilities and capacity for injectable dosage forms. This expansion allows the company to adeptly respond to the increasing demand of the high potency pharmaceuticals market.
Meeting occupational exposure limits (OEL) as low as 10 ng/cubic meter, the new HP injectable manufacturing line utilizes fully enclosed isolation systems and automated filling machines. According to the CDMO, the design effectively minimizes human intervention, preventing cross-contamination and ensuring quality assurance for sterile products. The line is equipped with two 20 square-meter lyophilizers, and supports liquid and lyophilized vials of various specifications, with a filling rate of up to 200 units per minute.